News >

Novel Approaches Make Headway in HER2+ Metastatic Breast Cancer

Kristi Rosa
Published: Thursday, Aug 01, 2019

Manali Bhave, MD, assistant professor, Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine

Manali Bhave, MD

HER2-targeted antibodies, antibody-drug conjugates (ADCs), immunotherapy, and TKIs have propelled metastatic HER2-positive breast cancer treatment forward, said Manali Bhave, MD, adding that more research efforts are focused beyond the first- and second-line settings.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x